Immunoexpression of ezrin and CD44 in patients with osteosarcoma

Journal of Pediatric Hematology/Oncology

Volumn 32, Issue 6, 2010, Pages e213-e217

  Boldrini, Erica ^a   Peres, Stela Verzinhasse ^a   Morini, Sandra ^a   De Camargo, Beatriz ^b  

^a Hospital Do Cancer de Barretos   (Brazil)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

CD44; Ezrin; Osteosarcoma; Prognosis

Indexed keywords

EZRIN; HERMES ANTIGEN; CYTOSKELETON PROTEIN; TUMOR MARKER;

ADOLESCENT; ADULT; ARTICLE; BRAZIL; CANCER RELAPSE; CELL MEMBRANE; CHILD; CYTOPLASM; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD; SURVIVAL RATE; TUMOR BIOPSY; BIOSYNTHESIS; BONE TUMOR; KAPLAN MEIER METHOD; METABOLISM; MORTALITY;

ADOLESCENT; ADULT; ANTIGENS, CD44; BONE NEOPLASMS; CHILD; CYTOSKELETAL PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; OSTEOSARCOMA; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77955892545     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181e5e247     Document Type: Article

References (21)

1. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986; 314: 1600-1606.
2. Huvos A. Bone Tumors: Diagnosis, Treatment, and Prognosis. 2nd ed. Philadelphia: W.B. Saunders; 1991; 134-149.
3. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med. 1999; 341: 342-352.
4. Holland JF, Bast RC, Morton DL, et al. Neoplasms of the Bone and Soft Tissue. In: Holland JF, Bast RC Jr Morton DL, et al, eds. Cancer Medicine. 4th ed. Baltimore: Williams and Wilkins; 1996: 3386, in two volumes, illustrated.
5. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol. 1994; 12: 423-431.
6. Brockstein BE. Metastatic osteosarcoma: a curable advanced malignancy. J Clin Oncol. 2004; 22: 5017-5018.
7. Yu Y, Khan J, Khanna C, et al. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med. 2004; 10: 175-181.
8. Moilanen J, Lassus H, Leminen A, et al. Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients. Gynecol Oncol. 2003; 90: 273-281.
9. Martin TA, Harrison G, Mansel RE, et al. The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol. 2003; 46: 165-186.
10. Raymond AK, Chawla SP, Carrasco CH, et al. Osteosarcoma chemotherapy effect: a prognostic factor. Semin Diagn Pathol. 1987; 4: 212-236.
11. Kim MS, Song WS, Cho WH, et al. Ezrin expression predicts survival in stage IIB osteosarcomas. Clin Orthop Relat Res. 2007; 459: 229-236.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
13. Khanna C, Wan X, Bose S, et al. The membrane cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004; 10: 182-186.
14. Park H-R, Jung WW, Bacchini P, et al. Ezrin in osteosarcoma: comparison between conventional high-grade and central low-grade osteosarcoma. Pathol Res Pract. 2006; 202: 509-515.
15. Weng EH, Ahlen J, Astrom K, et al. Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clin Cancer Res. 2005; 11: 2005.
16. Ferrari S, Zanella L, Alberghini M, et al. Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma. Pediatr Blood Cancer. 2008; 50: 752-756.
17. Xu-Dong S, Zan S, Shui-er Z, et al. Expression of ezrin correlates with lung metastasis in Chinese patients with osteosarcoma. Clin Invest Med. 2009; 32: 180-188.
18. Jamal HH, Aubin JE. CD44 expression in fetal rat bond: in vivo and in vitro analysts. Exp Cell Res. 1996; 223: 467-477.
19. Kim HS, Park YB, Oh JH, et al. Expression of CD44 isoforms correlates with the metastatic potential of osteosarcoma. Clin Orthop Relat Res. 2002; 396: 184-190.
20. Kim C, Shin E, Hong S, et al. Clinical value of ezrin expression in primary osteosarcoma. Cancer Res Treat. 2009; 41: 138-144.
21. Kuryu M, Ozaki T, Nishida K, et al. Expression of CD44 variants in osteosarcoma. J Cancer Res Clin Oncol. 1999; 125: 646-652.